PRESS RELEASE

July 16, 2026

Detect's Investigational Point-of-Care Platform Demonstrates Laboratory-Quality Molecular Results in 20 Minutes*

Detect's first molecular diagnostic for vaginitis establishes foundation for broader women's health menu

FOR IMMEDIATE RELEASE

GUILFORD, Conn., July 16, 2026 – Detect Inc. today announced that its investigational molecular vaginitis assay demonstrated high agreement with a market-leading FDA-cleared molecular comparator in a pre-clinical study.

The study evaluated 171 clinical specimens, comparing Detect's molecular vaginitis assay with an FDA-cleared molecular vaginitis test. Detect's assay demonstrated greater than 95% overall agreement with the comparator. The company's proprietary point-of-care platform also achieved a 99% valid test rate while delivering results within 20 minutes.

Detect's prototype molecular testing platform is being developed for use in physician offices and other point-of-care settings. The platform combines automated sample processing with a minimal hands-on workflow to deliver high-performance molecular testing and rapid, accurate diagnosis. The investigational vaginitis assay is the first to be developed for Detect's portfolio of rapid diagnostics that will run on its platform.

Detect's proprietary TruLAMP™ isothermal amplification technology powers the company's platform by incorporating a novel enzyme designed to enhance the sensitivity, specificity and speed of conventional LAMP chemistry. By delivering high-performance molecular detection without complex thermal cycling, TruLAMP™ enables simplified instrumentation and streamlined workflows while maintaining the accuracy required for molecular diagnostic testing. This flexible chemistry will enable menu expansion for a broad set of future assays on a single platform.

Vaginitis affects millions of women each year and is one of the most common reasons for gynecologic office visits. Accurate diagnosis based on symptoms alone can be challenging because the symptoms frequently overlap and mixed infections are common. Current molecular testing often requires specimens to be sent to centralized laboratories, delaying treatment decisions. Detect is developing its platform to provide laboratory-quality molecular testing at the point-of-care, where clinicians can make evidence-based treatment decisions during the patient's visit.

"Women deserve timely, accurate answers so they can receive the right treatment as quickly as possible," said Michelle Garsha, Chief Executive Officer of Detect. "These pre-clinical results demonstrate the strong performance of both our investigational molecular vaginitis assay and our proprietary point-of-care platform. Our vaginitis test is the first in a planned portfolio of diagnostics designed to bring laboratory-quality testing directly to the healthcare provider. By enabling providers to diagnose and treat patients during the same visit, we believe our platform has the potential to improve the patient experience, support better clinical decision-making, and expand access to a broad menu of tests in the future."

Detect will introduce the platform and share results from its pre-clinical study at the annual meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG), being held July 16-18 in Lake Geneva, Wis.

About Detect Inc.

Detect is a healthcare technology company focused on engineering an automated molecular diagnostic platform that delivers laboratory-grade accuracy to the point-of-care. The company's proprietary technology integrates streamlined sample processing with advanced diagnostic workflows and a versatile multimodal architecture to simplify high-performance testing. By eliminating the complexity of conventional molecular methods without sacrificing clinical precision, Detect is expanding access to rapid, evidence-based results. For more information, please visit www.detect.com.

*__For Investigational Use Only.__ The performance characteristics of this product have not been established.